NasdaqGM:PRCT
NasdaqGM:PRCTMedical Equipment

Why PROCEPT BioRobotics (PRCT) Is Up 8.3% After Raising 2025 Revenue Guidance

Earlier this month, PROCEPT BioRobotics Corporation reported its second-quarter and first-half 2025 earnings, highlighting sales growth to US$79.18 million for the quarter and a narrowing net loss of US$19.58 million compared to the previous year. The company also raised its full-year 2025 revenue guidance to approximately US$325.5 million, reflecting confidence in sustained sales momentum and operational improvements. We'll now consider how this raised full-year revenue guidance could...